

## Index

### **a**

- abbreviated new drug applications
  - (ANDAs) 350, 351, 456–458, 466, 469, 470, 473, 485, 486, 491
- abbreviated new drug approval (ANDA)
  - 47, 351, 453, 458, 461, 467–469, 486–489
- acoustic emission 224–226
- active pharmaceutical ingredients (APIs)
  - 1, 45, 325, 451, 482
  - characterization 68
  - chemical purity 505
  - crystallization strategy profiling
    - high-throughput (HT) crystallization method 74
    - organic CSP methods 74
    - screening types 75
  - and solid state
    - generics 483
    - proprietary 483
    - target 512
- aerodynamic particle size distribution (APSD) 335
- aerosolization performance 335
- agglomerates 29, 192, 194–196, 225, 256, 308–314
- aggregates 29, 192, 222, 509
- agitation 294, 296, 304–305, 311–313, 317, 424
- ALCOA+ principles 401
- Alizarin polymorphs 154
- Allotrope Data Format (ADF) 410
- allotropic forms 24
- alternative non-proprietary crystal form 501
- alternative proprietary crystal form 501
- alternative salts 502
- American Society for Testing and Materials (ASTM) 100, 409
- amlodipine besylate 337, 346, 428–429
- amorphous form 47, 67, 74, 307, 326, 343, 347, 349, 464, 466, 467, 502, 515
- amorphous material 22, 72, 73, 84, 94, 95, 110, 118, 121, 122, 134, 141–143, 503, 515, 517
- amorphous solid dispersions 343–344, 349, 503
- analyst reports and company financial reports 492
- analytic code 373, 375, 376, 379, 383
- analytic database system 373–375, 378
- analytic transfer tool 375–376
- Analytical Information Markup Language (AnIML) 409–410
- anhydrate (AH) 26, 30, 31, 154, 228, 252, 256, 333, 334, 337–339, 346, 347, 376, 424–426, 503
- anhydrous Aripiprazole crystals C, 435
- ANSI/ISA-88 408
- ansolvate 16, 26–28, 154, 385
- Anti-Stokes shifts 167
- antibody-drug conjugates (ADCs) 451
- Apotex's PHC anhydrate tablets 425
- Application Lifecycle Management (ALM) 413

Aripiprazole 435, 441  
 assessing validity of a patent 445–446  
 Atom Pair Distribution Function 110  
 atomic force microscopy (AFM) 91,  
 101–102  
 (ATR)-UV/Vis spectroscopy 219  
 attenuated total reflectance (ATR)  
 152–153, 219, 257, 281  
 avalanche photodiode (APD) 276  
 Avicel® RC-591 334  
 Axitinib 506

**b**

backscattered electrons (BSE) 96, 97,  
 100, 103  
 bake-on siliconization of cartridges 130  
 barium sulfate particles 284  
 BCS class 1 drugs 459  
 BCS class 2 drugs 459  
 BCS class 3 drugs 459, 460  
 Beer–Lambert relation 218, 219  
 Beer–Lambert’s law 258, 259  
 benchtop diffractometers 115  
 berberine chloride 338  
 bioavailability 46, 185, 196, 240, 314,  
 326, 331, 435, 457–459, 461, 464,  
 467–469, 495, 496, 508, 517  
 bioequivalence (BE) 86, 351, 454–458,  
 458–460, 462, 467–469, 475, 482  
 biological drugs (BLAs) 486, 491  
 Biologics Control Act in 1902 449  
 biopharmaceutical classification scheme  
 (BCS) 327, 331, 332, 342, 351,  
 458–460, 465, 467, 469, 495, 503,  
 507–509, 511, 517, 518  
 biowaivers 458–460  
 bispecific antibodies 451  
 blending 188, 206, 226, 345  
 Boltzmann transport equation 275, 276  
 Bragg’s law 109, 117, 229  
 Breakthrough Therapies 453  
 bright-field microscopy 92–93  
 British Pharmacopeia (BP) 337, 450  
 Brownian motion 187, 188

**c**

cable less connections 407  
 caffeine 231, 236, 338, 339, 345, 346, 348,  
 473  
 caffeine citrate 473  
 CALCIPOTRIOL monohydrate 444  
 Cambridge Structural Database (CSD)  
 61–62, 118  
 candidate profiling phase (CP-phase) 69,  
 73–77  
 Candidate Selection (CS) 329, 367, 485  
 CAR-T-cells 451  
 carbamazepine, (CBZ) 154, 155, 159,  
 161, 223, 224, 235, 251, 333, 338,  
 346, 348  
 carbamazepine–malonic acid cocrystals  
 154, 155  
 carbamazepine polymorphic system  
 159–162, 235  
 carboxymethylcellulose sodium 334  
 cefdinir 427  
 celecoxib 333  
 cell-therapies 451  
 Chemistry, Manufacturing and Control  
 (CMC) 2, 69, 78, 85, 86, 367–370,  
 387, 390, 391  
 chlorpropamide 231, 347, 348  
 chord length distribution (CLD)  
 222–224, 254, 255, 260–262  
 claims 47, 56, 58, 61, 171, 421, 422, 427,  
 428, 432, 433, 435, 441–445, 460,  
 461, 489–500  
 cloud point 222, 296, 297, 300  
 CMC project management 367–368  
 co-crystals 2, 25, 26, 110, 472–474, 502  
 regulatory framework 471–475  
 cohesion-adhesion balance (CAB) 336  
 Common Technical Document (CTD)  
 20, 466, 467  
 communication with CROs 381–382  
 computed tomography (CT) 203–210  
 $\mu$ CT 203  
 computer system validation (CSV) 144,  
 412  
 confocal microscopy 95

- consecutive scattering events 275
- content uniformity 158, 162, 168, 169, 171, 172, 176, 185, 192, 314, 334, 337, 342, 346, 455, 456
- tests 168
- continuous crystallisation 251, 265, 290
- contract development and manufacturing organizations (CDMOs) 8, 32, 367, 381
- contract research organizations (CROs) 32, 367, 381–382, 492
- Cooperative Patent Classification (CPC) 54–59
- core development project team (CDPT) 370
- CRISPR-CAS 451
- critical process parameters (CPP) 33, 35, 302, 316, 344
- critical quality attributes (CQAs) 302, 336, 337, 344
- cross-linked poly(acrylic) acid 338
- crystal form control 512–513
- crystal forms discovery
- analytical focus 507
  - irreproducibility of procedures 506
  - late appearing polymorphs 506
  - pragmatic questions 504–505
  - stage 503
  - unpredictability 503–504
- crystal structure prediction (CSP) 33, 74, 329, 330
- methods 329
- crystal-medium interfacial tension 333
- crystalline material 11, 21, 72, 74, 81, 82, 86, 94, 120–122, 124, 231, 234, 239, 441, 442, 472, 473
- crystalline paroxetine hydrochloride hemihydrate 425
- crystalline posaconazole 347
- crystallisation processes selection
- process exploration 300–302
  - process outline evaluation 299–300
  - process outline selection 298–299
- crystallization 1, 11, 23, 31
- laboratory 2–3
  - of impurities and intermediates 389
  - processes 387–388
- Crystallography Open Database 61, 62, 118
- cyclic DSC measurements 134, 136, 138, 139
- cyclodextrins 332
- cytochrome P 450 (CYP450) 50
- d**
- DailyMed 491–492
- dark-field microscopy 93
- data exclusivity 481, 485, 486, 489–490, 492
- data mining algorithms 9
- Decision “Kristallformen” German Federal Court 443
- Decision Point (DP) 11, 12, 20, 291, 325–328, 330–332, 335–337, 344–346, 349–351, 367, 369, 370
- Decision T 1555/12 dated April 29, 2015 435, 441
- Decision T 2114/13 dated October 12, 2016 442
- Decision T 2397/12 dated March 12, 2018 442–443
- Decision T 246/15 dated November 13, 2018 442–443
- Decision T 777/08 of May 24, 2011 435
- Decision X ZR 110/16 dated August 7, 2018 444–445
- Decision X ZR 58/08 dated March 15, 2011 443–444
- Decision X ZR 98/09 dated May 15, 2012 444
- dehydrated form or anhydrate 26
- delivered dose uniformity (DDU) 335
- dependent light scattering 277–280
- Design of Experiment (DoE) 176, 177, 180, 260, 284–285, 301, 344, 346, 388
- designations and code assignment 371–373
- desolvate or desolvated form 26
- Deutsche Arzneibuch (DAB) 450

- Developability Classification System (DCS) 327, 331
- diethylene glycol 449
- differential scanning calorimetry (DSC)
  - cyclic measurements 134
  - detection limit of 134
  - evaluation 132–134
  - fast scanning calorimetry 134
  - heat flux 131
  - modulated DSC, 134
  - power compensation 131
  - sample preparation and measuring parameters
    - gas atmosphere 132
    - heating 132
    - sample pan 132
    - sample weights for 132
- diffusion coefficient 221, 271, 333
- digitalization
  - application 18–20
  - fully digitalized infrastructure 20–21
  - in laboratories
    - Ad hoc analysis 401–402
    - centralized archiving 401
    - data integrity requirements 400–401
    - data value 402–403
    - Increasing throughput 400
    - IT systems 403–406
    - repeatability 400
    - staff expectation 398–400
  - pre-requisites-technology and people 13–15
- Directive 2001/83/EC [29] 461
- Directive 2001/83/EC, Article 10(1) 457
- dispersed primary particles 29
- disrupted crystal 515, 516
- dissolution 335
  - profiles 2, 158, 185, 209, 457, 509
  - rate 29, 70, 72, 85, 102, 196, 216, 332, 333, 335, 337, 342, 349, 351, 452, 455, 456, 467, 496, 509
- documentation 13, 36, 180, 316, 317, 366, 378–381, 383, 386, 388, 392, 405, 410, 413–416
- downstream processes 289, 301, 302, 308, 314, 315, 379, 389
- drug development and drug product processing
  - blending 188, 206, 226, 345
  - co-crystal formation/complexation 328
  - control strategy 349–350
  - different stages 328
  - film coating 348
  - formulation development 330–332
  - galenical tetrahedron 325–326
  - granulation 346–347
  - hydrate formation 328
  - manufacturability (processability) 326
  - particle size reduction 345
  - pharmaceutical profiling 328–330
  - regulatory submissions 350–353
  - salt disproportionation 328
  - solid form screening 326
  - structured development approach 325
  - tablet compression 347–348
- Drug Master Files (DMFs) 481, 491
- drug polymorphs 332
- The Drug Price Competition and Patent Term Restoration Act 485
- drug product bioavailability (BA) 326, 328–335, 337, 342, 343, 349, 351, 458, 467, 468, 508
- drug product intermediates 185, 472
- drug product performance testing 466, 469
- drug product stability and manufacturability 331
- dry granulation 336, 346, 347
- drying 308–309, 311–313, 338–339, 346–347
- dry powder inhalers (DPIs) 97, 335, 336
- dynamic light scattering (DLS) 188–189, 221, 273, 274
- dynamic solubility measurement 296, 297
- Dynamic Vapour Sorption (DVS)
  - experiments 23, 27, 77, 373, 377, 383, 385, 387, 465, 515

**e**

- electron microscopy
    - SEM 96–100
    - TEM 100
  - electronic lab/laboratory notebooks
    - (ELNs) 13, 14, 17, 372, 378, 381, 386, 392, 398, 403, 404
    - documents 379–380
  - electronic laboratory journal 378, 381, 392
  - electrospinning 343
  - electrozone sensing equipment 187
  - elemental impurities 450
  - enabling formulations 452
  - energy dispersive X-ray spectrometry (EDS) 96–100
  - Enterprise Resource Planning (ERP) 20, 403, 405, 406
  - equilibrium solubility 297–298, 329, 332, 335, 508
    - measurement 297–298
  - escitalopram oxalate 473
  - Espacenet 56–59
  - essential similarity 482, 490, 520
  - Ethernet adapters 407
  - European Federation of Pharmaceutical Industries and Associations (EFPIA) 7
  - European Medicines Agency (EMA) 26, 46, 145, 205, 350, 351, 450, 454–457, 474, 475, 492
  - European Patent Convention (EPC) 432, 433
  - European Patent Office (EPO) 54, 431
    - Decision T 1555/12 dated April 29, 2015 435, 441
    - Decision T 2114/13 dated October 12, 2016 442
    - Decision T 2397/12 dated March 12, 2018 442
    - Decision T 246/15 dated November 13, 2018 442–443
    - Decision T 777/08 of May 24, 2011, 435
    - polymorph 436–440
  - European patents
    - economic factors 432–433
    - European Patent Office 431–432
    - polymorph screening 434–435
    - protection of polymorphs and solid forms 433–434
    - Unitary Patent 433
  - European Pharmacopoeia (EP) 145, 155, 180, 205, 450, 469, 471
  - European Public Assessment Reports (EPARs) 492
  - European Union (EU) 145, 176, 316, 423, 454, 455, 457, 458, 460, 461–463, 475, 489, 490, 492, 502
  - Excel sheets 15
  - experiment code 372, 373, 378
  - exploratory crystallization experiments
    - 400mg-crystallization experiments 84–85
    - Form VI and citric acid compound Form 86–87
    - HT-screening setup 83
    - XRPD data 81
  - extemporaneously prepared oral suspensions 334
  - extended defects 216
  - extended European search report (EESR) 431
  - extractables 450
- f**
- fast scanning calorimetry 134, 145
  - Fasted State Simulated Intestinal Fluid (FaSSiF) 70, 77, 86
  - Febuxostat 442
  - Fed State Simulated Intestinal Fluid (FeSSiF) 70, 77, 86
  - Federal Food, Drug and Cosmetic Act 449, 460, 461
  - Federal Patent Court and the German Federal Supreme Court
    - Decision “Kristallformen” German Federal Court 443

- Federal Patent Court and the German Federal Supreme Court (*contd.*)
    - Decision X ZR 110/16 dated August 7, 2018 444–445
    - Decision X ZR 58/08 dated March 15, 2011 443–444
    - Decision X ZR 98/09 dated May 15, 2012 444
  - Feret's diameter 186
  - field of vibrational spectroscopy 165
  - film coating 102, 348
  - filtration 295, 308–311
  - filtration process 16, 17
  - fluconazole 472
  - fluid bed granulation 346
  - fluorescence microscope 95–96
  - focal plane array detectors (FPA) 156–157
  - Focused Beam Reflectance Measurements (FBRM) 222–223, 237–238, 254–257, 260, 281, 391
  - Food and Drug Administration (FDA) 46, 145, 205, 249, 342, 350–351, 401, 424, 428, 449–450, 454–460, 466, 468–470, 473–475, 486–491
  - Fraunhofer model 190
  - free patent databases
    - Espacenet 58–59
    - Google Patents 57–58
    - Lens.org 60–61
    - Patentscope 59–60
  - freedom to operate (FTO) 37, 48, 52, 487–488, 499, 501, 503, 519
  - freeze-dry microscope 96
  - Freundlich–Ostwald equation 333
  - FTIR microscopy 156, 162
  - fully digitalized infrastructure 20–21
  - fundamental lab processes 382
- g**
- galenical tetrahedron 325–326, 330
  - Gartner IT Glossary 13–14, 398
  - generic commercial success 522–523
  - generic drug development
    - formulation development 496–497
    - stability question 497–498
  - generic exclusivity 486
  - generic solid state development
    - additional factors 509
    - alternative non-proprietary crystal form 501
    - alternative proprietary crystal form 501
    - alternative salts 502
    - amorphous form 502–503
    - amorphous solid dispersions 503
    - analytic focus 514–515
    - API target 511–512
    - cocrystals 502
    - crystal form control 512–513
    - crystal forms discovery 503–507
    - impact on formulation 517–518
    - intellectual property 519
    - lot-to-lot variability 513–514
    - micronized crystalline APIs 516
    - morphology 509
    - particle size and morphology 513
    - polymorph patent landscape 499
    - polymorphic purity 512
    - process development 510
    - solid state stability 509, 517
    - solubility 508–509
    - solubility curves 510–511
    - tetrahedron principle and consistency 516
    - thermodynamic stability relationships 510
  - generics 481–483, 490, 494, 502, 506, 520
  - genotoxic impurities 450
  - german DESTATIS GENESIS-online database 7
  - global substance codes 372
  - glyceride-based lipid vehicles 342
  - good manufacturing practice (GMP) 119, 145, 316–317, 367–368, 405, 449–450, 475
  - Google Patents 56–58
  - Google Patents search 52, 57

- granulation 188, 205–206, 226, 252–253, 255, 336–339, 346–348, 351, 391, 475, 498, 517, 520–521
- griseofulvin 339, 348
- h**
- Hatch–Waxman Act 485
- heat flux DSC, 131–132
- heat of fusion rule 139–140
- heat of transition rule 139
- hemihydrate (HH) 338, 346, 424–426, 490
- heptane 329
- herbicide 443
- high frequency amplifier (HFA) 276
- high permeability 459
- high pressure liquid chromatography (HPLC) 23, 28, 158, 168–172, 301, 373, 375, 377, 383–384
- high solubility 389, 459, 465
- high-throughput (HT) crystallization method 74
- high-throughput screening (HTS) 328, 385–387, 451
- highly soluble API powder 514
- hot-melt extrusion (HME) 252, 343, 452, 466, 475
- hybrid application 461–462
- hydrate 25–27  
     formation 328  
     solid forms 26–28
- hydrophilic co-solvents 342
- hydroxypropyl cellulose 338
- hygroscopicity 27–28, 78, 216, 326, 331, 435, 452, 465, 468, 508–509, 514, 518
- hypromellose 338–339
- hypromellose acetate succinate 339
- i**
- ibuprofen solid state polymorphism 50–51
- imatinitib mesylate 491
- in situ analysis, monitoring solid state processes
- benefits 236–240
- classification of 217
- crystallisation from solution  
     light scattering 221–224
- crystallisation kinetics from solution  
     infrared spectroscopy (IR) 219–221  
     UV-Vis spectroscopy 218–219
- extrinsic solid properties  
     acoustic emission 224–226  
     thermography 226–228
- intrinsic solid properties  
     Raman spectroscopy 232–236  
     X-ray diffraction 228–232
- PAT techniques 241–242
- solid material 215–216
- solid products 216
- solution-phase processes 218
- inelastic scattering 166, 232–233
- infrared (IR) microscopy  
     imaging methods, drug development measurement setups 157–158  
     spatial resolution 156–157
- infrared (IR) spectroscopy 219, 470  
     absorption of 151
- case studies  
     carbamazepine polymorphic system 159, 161–162  
     NIR-IR-mapping component detection 158–160
- drug substances  
     analysis and reporting 153–154  
     ATR 152–153  
     carbamazepine–malonic acid cocrystals 154–155  
     identification method 155–156  
     IR microscopy and imaging 153  
     Oxatomide 154  
     quantification methods 156  
     transmission mode 152
- innovative/ethical product 482
- intellectual property 13, 35–36, 46–47, 54, 57, 421, 443, 453–454, 487, 490, 519–520
- International Confederation for Thermal Analysis and Calorimetry 129

- International Council of Harmonization (ICH) 28, 76, 103, 120, 145, 155–156, 158, 180, 196, 290, 293, 302, 316, 325, 328, 344, 349–350, 367, 378, 450, 463–464, 466–467, 469
- international nonproprietary name (INN) 372
- International Patent Classification (IPC) 54, 59
- international patent system (PCT) 36, 490, 500
- International Requirements Engineering Board (IREP) 413
- International Tables of Crystallography 22
- investigational new drugs (INDs) 456–457
- IT modernization 14
- Itraconazole–Soluplus solid dispersion 348
  
- j**
- Jablonski Energy Diagram 166
- Japanese Pharmacopoeia (JP) 450
  
- k**
- key starting materials (KSMs) 487–488, 521
- kinetic stability 292, 307, 497, 508–509
- Kinetisol® technology 343
- Knoevenagel condensation 232–233, 236–237, 239
- knowledge gathering process 45–46
  
- l**
- Lab Execution Systems (LES) 404
- laboratory codes 372, 383, 392
- Laboratory Information Management Systems (LIMSs) 17, 20, 372, 376, 381, 392, 398, 403–404
- laboratory IT systems
  - data analysis and reporting 405–406
  - data exchange
    - adapters 407
    - Allotrope Data Format 410
    - AnIML 409–410
    - ANSI/ISA-88 Batch control (S-88) 408
    - Common data formats 409
    - file based communication 408
    - OPC UA 408
    - SiLA 408–409
  - devices 403–404
  - ERP 405
  - hierarchical categories of 403
  - implementation of
    - Contextual inquiry 411
    - CSV 412
    - interaction room 411–412
    - IREP 413
    - realization 415
    - risk management 414
    - rollout 416
    - Specification 414
    - usability 414
    - verification 415–416
  - Lab Data Systems 404–405
  - LES 404
  - SDMS 404
- lactose monohydrate 99, 283, 338
- laser diffraction 94, 98–99, 185, 188–199, 261, 300–301, 465
- laser direct infrared (LDIR) 158–159
- late appearing polymorphs 505–506
- leachables 450
- Lead Optimization phase (LO-phase) 68
- left-over crystal forms 503
- legal expenses 487
- Lens.org 60
- light scattering 110, 188–189, 197, 221–224, 236, 250, 273–279, 281, 285–286
- light-diffraction approach 186
- lipid formulation classification system (LFCS) 342
- lipid-based drug delivery systems (LBDDS) 342
- lipid-based formulations 339–343
- liquid dosage forms 332–333, 335



- liquid formulations 332–335, 391  
 local defects 216  
 local substance codes 372  
 lot-to-lot variability 513–514, 516  
 low soluble APIs 515
- m**
- machine learning 15, 259, 374, 392, 403  
 magnesium stearate 339  
 maleic acid 372, 472  
 manual ELN review process 380–381  
 manual screening 75, 384–385  
 manufacturing classification system (MCS) 336  
 market exclusivities 461, 486, 489–490  
 Martin's diameter 186  
 material flow 371  
 materials of construction (MoC) 294, 303–304  
 materials science tetrahedron (MST) 325, 516  
 mathematical formulas 33  
 mechanochemical Knoevenagel condensation 233, 237, 239  
 mechanochemistry 218, 231–232, 235  
 mechanosynthesis of manganese phosphonate 239  
 melting point (MP) 77–79, 84, 134, 139–140, 294, 331, 342–343, 402, 443, 452, 465, 470  
 Metal Organic Framework (MOF) 111, 236  
 metastable forms 85, 250, 255, 257, 265, 292, 304–308, 315, 328, 333, 376, 385, 496–498, 501, 508–509, 511–512, 517–518, 520  
 meta-stable zone width (MSZW) 31, 296–297, 306–307  
 metronidazole benzoate 334  
 Micro X-Ray Computed Tomography ( $\mu$ CT)  
 advantage 204  
 definition 203  
 pharmaceutical industry coating characterization 207–208  
 density distribution 205, 206  
 foreign matter detection 210  
 performance evaluation 209–210  
 porosity determination 205  
 porous characterization 205–206  
 size, shape and dimensions and interfaces 207  
 micro-project management 369–370  
 microcrystalline cellulose (MCC) 334, 338–339, 346  
 micronized crystalline APIs 514, 516  
 microprecipitation 343  
 microscopy  
 AFM 101–102  
 definition of 91  
 electron 96–100  
 in regulatory documents 103  
 optical microscopy 91–96  
 Mie model 191  
 Mie theory 94, 190–191, 199, 277–279  
 modulated DSC, 134, 141–143  
 Molecular Complementarity (MC) 74  
 Molecular Electrostatic Potential (MEP) 74  
 monoclinic metazachlor 443–444  
 30-month stay 486–487  
 morphic forms 24–25, 452, 456, 463, 465–471  
 motivations 4–6, 48, 365, 398–403, 444  
 MRI Product Index 492  
 multivariate methods 169, 173  
 multivariate models 175, 181, 221  
 Mutual Recognition Product Index 492
- n**
- naproxen sodium 337–338, 346–347  
 Natrosol suspension 70–73  
 NCE-1 486–488  
 near infrared (NIR) spectroscopy 157–160, 166, 220, 250, 252–254, 259, 347  
 needle-like crystals 92, 336  
 new active substances (NAS) 46, 115, 463, 475

- new chemical entities (NCEs) 47, 67–69,  
75, 79, 367–368, 370, 457, 483,  
486–489
- New Dosage Form (NDF) 486
- new drug applications (NDAs) 20, 151,  
328, 350, 453, 456, 460–461,  
485–486, 488–489, 491
- new drug approval (NDA) 453
- nitrofurantoin 337
- non-material sense, impact of 5
- non-solvated form 26–29
- non-speaking codes 371
- nonstoichiometric hydrate (NSH) 30–31,  
346, 348
- Norvasc® 9, 428
- Noyes–Whitney equation 333, 335
- Nucynta® products 423
- O**
- olanzapine 338
- One Compound Report 79
- Open Platform Communications Unified  
Architecture (OPC UA) 281, 408
- optical coherence tomography (OCT)  
203
- optical microscopy  
bright-field illumination 92–93  
confocal microscopy 95  
dark-field conditions 93  
fluorescence microscope 95–96  
freeze-dry microscope 96  
PLM 93–95  
thermal microscopy 95  
use of 92
- oral compounding 334
- oral liquid formulations 332
- oral solid dosage forms 169, 336, 482
- Orange Book (OB) 485–486, 489–491
- organic compounds 1, 24, 28, 55, 62, 97
- Organikum 1
- Orphan Drug Exclusivity (ODE) 486
- orthogonal signal correction (OSC) 260
- Ostwald ripening 280, 334
- Oxatamide 154
- oxygenation/deoxygenation of blood 277
- P**
- P1-approximation 275–276
- Palexia® 423
- paragraph IV (PIV) 486
- parallel experiment codes 372–373
- paroxetine hydrochloride (PHC)  
424–426, 490
- Partially Automated Solubility Screening  
test (PASS) 329
- particle size 29  
cumulative distribution curves 186,  
187  
DLS 188–189  
electrozone sensing equipment  
187–188  
Feret’s diameter 186  
laser diffraction 189  
Fraunhofer model 190–191  
inconsistent disconnected peaks  
197–198  
instrumentation and measurement  
189–190  
method validation 196–197  
Mie model 191  
repeatable artifact peaks 199  
sample dispersion 192–195  
sample representativeness and  
obscuration 195–196  
light-diffraction approach 186  
Martin’s diameter 186  
microscopy techniques 188  
projected area diameter 186  
sedimentation methods 187  
sieving 188
- particle size and morphology 310–311,  
314, 509, 513
- particle size distribution (PSD) 29,  
71–72, 99, 110, 185, 187, 198–199,  
222–224, 237, 271, 279, 295,  
330–331, 334–337, 344, 349,  
390–391, 495, 498, 508, 513–516
- particle size range 272, 274
- particle size reduction 301, 314–315, 345
- particle-sizing technologies 271–273,  
300

- partition coefficient 68, 342
- patent
  - assessing validity of 445–446
  - claims 421
  - definition 421
  - patent prosecution 422
  - professionals 446–447
  - right to exclude 422
  - rules and requirements for 421
  - United States 422–429
- patent certification 486
- Patent Cooperation Treaty (PCT) 36, 490, 500
- patent owner's exclusive rights 432
- patent prosecution 422
- patentable subject matter 422
- Patentscope 56, 57, 59–60
- pay data sources 492–493
- Percus–Yevick approximation 278
- permeability 326, 329, 331, 342, 351, 459, 463, 468, 482
- personal dimension 5–6
- pharmaceutical alternatives 454–460
- pharmaceutical application 2, 10, 92, 116, 118, 120, 123, 171
- pharmaceutical development 3, 10, 32, 95–97, 100, 153, 325–328, 350, 366, 382, 398, 400, 463, 476
- Pharmaceutical Discussion Groups (PDGs) 450
- pharmaceutical equivalence 454–456, 458, 460
- pharmaceutical industry 2, 7–9, 31, 36, 91, 100, 107, 129, 162, 165, 185, 203–210, 251, 290, 308, 315, 325, 365, 397–416, 434, 449–453, 471, 476, 506
- pharmaceutical profiling 325, 328–330
- pharmaceutical salts 452
  - bioequivalence 456–458
  - biowaivers 458–460
  - pharmaceutical alternatives 454–456
  - pharmaceutical equivalence 454–456
  - regulatory approval pathways in the European Union 461–463
  - regulatory approval pathways in the United States 460–461
  - therapeutic equivalence 458
- pharmaceutical solid state development 4–5
- pharmacopoeia, polymorphism in 469–471
- phase diagrams 11, 23, 79, 230, 298
- PHC hemihydrate 424–426
- Photon Density Wave (PDW) spectroscopy
  - absorption and scattering properties 275
  - experimental setup of 277
  - optical emission and detection fibers 276
- P1-approximation 275
- particle size 277–279
- process analysis 282
  - barium sulphate precipitation 284–285
  - lactose crystallization 283–284
- sample versus process measurements 280–281
- technical implementation and data
  - access 281–282
  - time-dependent 275
- physical sample transfer 375
- plume geometry 335
- polarized light microscopy (PLM) 92–94
- polychromatic radiation 113–114
- polyethylene glycol 338–339
- polymorph patent landscape 499–500
- polymorph screening 56, 75, 325, 350, 423–424, 434–435, 446, 452, 488, 499, 501, 504
- polymorphic forms 11, 23–26, 30–32, 36, 46, 55–57, 70, 81, 84, 119, 153–154, 156–157, 159–162, 167, 173, 215–216, 220, 231, 235–236, 310, 349, 351, 368–370, 379, 385, 387, 390, 427, 429, 434, 441, 442, 445, 452, 467–468, 519, 521
- polymorphic landscape 23, 29–31, 47, 69, 74, 329

- polymorphic purity 251, 257, 496, 511–512
  - polymorphic stability
    - in dry conditions 497–498
    - in wet conditions (slurry) 498
  - polymorphism 2
    - allotropic forms 24
    - definition 24
    - modification 24–25
    - morphic form 25
    - morphology 24
    - in pharmacopoeias 469–471
  - polymorphs 433
    - regulatory approval for 463–469
  - population balance equation (PBE) 262–263, 265
  - portfolio management
    - analyst reports and company financial reports 492
    - business case 493
    - criteria for building a robust portfolio 494–495
    - criteria for identifying promising projects 493–494
    - data exclusivity 486, 489–490
    - European Union (EU) 489
    - legal expenses 487
    - 30-month stay 486–487
    - NCE-1 486
    - Orange Book (OB) 485–486
    - paragraph IV (PIV) 486
    - patent certification 486
    - pay data sources 492–493
    - project evaluation 491
    - Quality Target Project Profile (QTPP) 493
    - risk management 487
    - salts and esters 490
    - starting material 487
    - strategy 484
    - think global, act local 490–491
    - timing 487–488
    - US FDA 489, 491
    - value 484–485
  - posaconazole 339, 347
  - potential critical material attributes (pCMA) 331, 344
  - potential critical process parameters (pCPP) 344
  - povidone 338
  - powder X-ray diffraction (P-XRD) 83, 111, 120, 465
  - powder X-ray diffractometers 115
  - power compensation DSC, 131
  - preclinical formulations 70–73, 391
  - pre-CMC data 369
  - precipitation 11, 16, 23, 75, 218, 264, 280, 282, 284–285, 307–308, 332–333, 342–343, 452, 503, 509, 513
  - preferred orientation 114, 116–118, 124
  - pressure-induced transformations 339
  - pressurized metered dose inhalers (pMDIs) 334
  - probe fouling 280–281, 283
  - process analytical techniques (PAT) 19, 21, 210, 236–237, 240–242, 249, 251, 280–281, 284, 299–302, 308, 388–389
  - process-induced transformations (PIT) 167, 325, 328
  - product-specific guidances for generic drug development 491
  - project codes 372, 375
  - project evaluation 491–493
  - projected area diameter 186
  - proprietary products 482–483
  - pseudo-polymorphs 2, 452, 464, 469, 476
  - PubMed 48–51, 60, 491
  - purified Rifaximin  $\alpha$  445
  - Purple Book 491
- q**
- quality by design (QbD) 179, 249, 253, 325–326, 330
    - principles 35
  - Quality Risk Assessment (QRA) 316–317, 344

quality target product profile (QTPP)  
325, 330–331, 336, 491, 493

Quantum Cascade Laser (QCL)  
technology 158

**r**

radiation 22, 91, 93, 96, 107, 109,  
111–114, 121, 151, 157, 165,  
203–204, 217, 219–222, 226,  
229–230, 232–233

Raman active 166, 174–175, 250

Raman effect 165–167, 233

Raman spectroscopy 154  
history of 165  
objective 165  
pharmaceutical purposes  
fibre optic probes 167–173  
TRS 167  
Raman effect 166  
solid form monitoring 250–252

ranitidine hydrochloride (RHCl)  
426–427

rapidly dissolving 459–460

recrystallized CBZ (REC) 223–224

reference listed drug (RLD) 46, 351, 458,  
468–469, 486–487, 491, 495–496,  
499, 507–509, 517, 519

reference medicinal product 457

reflection geometry 113–115, 387

refractive index (RI) 94, 152–153, 190,  
222, 276, 279

regulatory approval for polymorphs  
463–469

regulatory approval pathways in the  
European Union 461–463

repeatable artifact peaks 199

replica experiments and scale-up phase  
387

Resonant Acoustic Mixing 227

Rietveld full pattern refinement 124

Rietveld refinement 123–124

Rifaximin 445

right to exclude 422

risk management 18, 32, 180, 316, 414,  
416, 487, 499

RNA drugs 451

roller compaction 347

route scouting process 389

**S**

salt-cocrystal 9, 25–26, 81, 84, 329

salts and esters 490

same active substance 454, 456–457,  
462, 502

sample code 372–373, 379

sample dispersion  
dry dispersion 194–195  
wet dispersion 192–194

saturation solubility 333, 384

scale up and technology transfer process  
390

scale-up a crystallisation process  
accommodation  
agitation 304–305  
heat transfer 305  
solid additions 305–306  
solution addition 305  
sonication 306  
vessel size and MoC 304

agglomeration 314

drying 311–313

filtration and washing process 310,  
311

isolation 309–311

parameters 303

particle size reduction  
delumping 314  
milling or micronisation 314  
storage and Packing 315

risk of  
amorphous forms 307–308  
metastable forms 307  
oiling and phase separations 308,  
309  
salt stoichiometry 308

scanning 13–14, 23, 53, 91, 158, 185,  
219–220, 262

scanning electron microscope (SEM)  
96–100, 103, 188, 199

- Scientific Data Management Systems (SDMS) 404–405
- secondary electron (SE) emission 96–97, 100
- sedimentation methods 187
- self-emulsifying drug delivery systems (SEDDS) 339
- self-microemulsifying drug delivery systems (SMEDDS) 339
- Serial Port (RS232) 407
- sieving 185–186, 188, 386
- silica 107, 110, 339, 343
- silicified microcrystalline cellulose 338
- single crystal X-ray diffraction 22, 110–112, 137, 465
- S.M.A.R.T. principles 29
- societal impact, fishing in foreign waters
  - individuals impact 6–7
  - market impacts 7–9
  - motivation 4–5
  - personal dimension 5–6
  - professional data 9
- sodium naproxen 337
- soft gelatin capsule 342
- solid 13C-NMR 441
- solid dosage forms 152, 158–159, 167, 169, 185, 203–204, 206–207, 210, 332, 335–339
- solid form landscape 67, 136, 139, 145, 330
  - thermal analysis 130
- solid form monitoring techniques
  - advantages and challenges of 257–258
  - direct characterization techniques
    - NIR spectroscopy 252–253
    - Raman spectroscopy 250–252
  - indirect monitoring tools
    - FBRM 254–255
    - in-process microscopy 256
    - solute concentration 256–257
- solid form screening 74–75, 79, 326
- solid form transformation modelling
  - data-driven model for CLD-PSD
    - prediction 260–262
  - multivariate data analysis 259–260
  - polymorph transformation processes 262–265
- solid forms 433
  - agglomerates 29
  - aggregates 29
  - amorphous material 22
  - ansolvate 26–28
  - crystal water, nomenclature of 27
  - crystalline material 21–22
  - crystallization 11–13, 23, 31–32
  - digitalization
    - application 18–20
    - filtration 16, 17
    - fully digitalized infrastructure 20–21
    - pre-requisites-technology and people 13–15
    - triangle of project management 18
  - dispersed primary particles 29
  - diversity of 10
  - hydrate 26–28
  - in-silico techniques 32–35
  - intellectual property rights 35–36
  - multi-component compounds 25–26
  - non-solvated form 26–28
  - optimization of crystallization
    - processes 32
  - organic solvents 26, 27
  - particle size 29
  - particle size distribution 29
  - polymorphic landscape 29–31
  - polymorphism 24–25
  - precipitation 23
  - simulation techniques 32–35
  - solid state properties 32
  - solid-liquid and solid-solid systems,
    - phase diagram 23
  - synthesis procedure 13, 14
- solid forms on API scale-up
  - crystallisation development process 290
  - crystallisation scale up 302–315
  - people and skill requirements 315
  - regulatory requirements
    - process documentation 316

- quality and manufacturability
  - framework 316
- safety assessment 316
- small scale crystallisation development
  - crystallisation processes selection 298–302
  - form selection 291–293
  - process development 302
  - solvent selection 293–298
- solid fraction range 272–274
- solid material 11, 16, 31, 36, 69–72, 82–83, 86, 118, 215–216, 240, 242, 306
- solid products 216–217, 219–221, 240
- solid solutions 10, 343–344, 474
- solid state characterization techniques 1, 9, 91–103, 129–145, 151–162, 185–199, 228, 249
- solid state evaluation
  - early drug discovery phase 68–69
  - in research and development
    - API-crystallization strategy profiling 73–77
  - in pre-clinical formulations 70–73
  - screening types 76
- knowledge management 79
- selection criteria
  - physico-chemical parameters 78
  - solid state properties 77–78
- solid form properties
  - analytical characterization of 81
  - compound A 81
  - exploratory crystallization
    - experiments 81–86
    - medicinal chemistry 80
- solid state laboratory processes 399–400
- solid state stability 291, 508–509, 513, 517
- solid-chem GmbH 8
- solid-state development 2–6, 12, 24, 46, 365–370, 373, 377, 382, 391–392, 411, 449–476, 483, 490, 495, 498–520
- solid-state forms
  - general regulatory considerations for pharmaceutical 453–454
  - to be used for dugs 451–453
- solid-state lab
  - high-throughput (HT) screening 385–387
  - initial testing 382–384
  - manual screening 384–385
  - replica experiments and scale-up phase 387
  - solubility estimation 384
- solid-state project
  - Crystallography Open Database 62
  - CSD 61–62
  - knowledge gathering process 45
  - literature search
    - Boolean operators 49
    - ibuprofen solid state polymorphism 50–51
    - latest publications 51
    - PubMed 49
  - patent and intellectual property 47
  - patent search
    - classification 54–56
    - database 56–61
    - free patent databases 57–61
    - freedom to operate searches 52
    - landscape report 52
    - patent landscape report 52
    - patent map 52
    - reports 53
    - regulatory perspective 46
- solubility 508
  - curves 510–511
  - data report 379
  - enhanced formulations 339–344
  - estimation 384
- solubility and residual solid screening (SORESOS assay) 329
- solubility measurement
  - dynamic 296–297
  - equilibrium 297–298
- solution-mediated transformation 345–346, 498

- solvent 25
  - mediated phase transformation 338
  - mediated transformations 339
- solvent selection
  - examples 293
  - solubility diagram 294–295
  - solubility measurement 295–296
  - solvent screening 293–294
- sonication 197, 306
- space group 22, 62, 108, 110, 507
- space group symmetry 108–109
- speaking code 371, 373
- spray pattern 335
- sprints 415
- squalamine dilactate salt 442
- stability storage process 377–378
- Stability Testing of new Drug Substances and Products 28
- stakeholders 2, 12, 18, 20–21, 36, 366, 369, 406, 411, 414
- standard normal variate (SNV)
  - transformation 260
- standard operating procedures (SOP) 382, 416
- Standards and Trends in Solid State Characterization Techniques 129–146, 151–162, 249
- Standards in Lab Automation (SiLA) 408–410
- starting material 13, 71–72, 217, 233, 237, 383, 386, 487
- static light scattering (SLS) 188, 221, 223, 286
- Stokes signals 167
- structured product development 325
- substance requirement plan 368
- successful biostudy 520–521
- sulfaguanidine 338, 346
- supercritical fluid technology 343
- surfactants 193, 198, 332–334, 342–343, 520
- symmetry 21–22, 108–110, 216, 229
- t**
- tablet compression 346–348
- tapentadol hydrochloride 423–424
- tapping mode 101
- tasks and duties, solid state development 12
- telmisartan 465
- temperature cycling 302, 306
- tetrahedron principle and consistency 516
- texture effect 116–118, 121–123
- theophylline 253, 337–339, 346
- theophylline co-crystals 334
- therapeutic equivalence 454–455, 458, 460, 482, 485, 491
- thermal analysis
  - case studies
    - amorphous phases 141–142
    - polymorphic transitions 136–139
    - solvate structures 142–145
    - ultra-fast heating rates 139–141
  - definition 129
  - DSC 131–136
  - in drug development
    - compatibility studies 130
    - phase transitions 131
    - solid form landscape 130
  - quality and regulatory aspects 144–145
  - TGA 134
- thermal microscopy 95
- thermocouples 226–228
- thermodynamic stability 23, 497, 517
- thermodynamic stability relationships 510
- thermogravimetric analysis (TGA)
  - bottom-loading 134
  - evaluation 135–136
  - gas analysis 136
  - heating rates 136
  - of calcium oxalate monohydrate 142, 144
- sample preparation and measuring
  - parameters
    - gas atmosphere 135
    - heating rates 135
    - sample pan 135
    - sample weight 135



- side-loading 134
  - top-loading 134
  - thiamine hydrochloride 30, 338, 346, 348
  - three dimensional physical world 5
  - time-independent photon density 275–276
  - timely measurement 376–377
  - timing 481–485, 487–488, 490–491, 494, 500
  - tolbutamide 348
  - tolerable daily intake (TDI) 76
  - tramadol 170, 174
  - transmission electron microscopy (TEM) 96, 100, 273
  - transmission mode 114, 117, 119, 152, 157, 167, 219
  - transmission Raman spectroscopy (TRS)
    - advantages 168
    - business case 171–173
    - definition 174
    - evaluation phase
      - feasibility 176–177
      - pre-feasibility evaluation 174–176
    - model development, calibration and validation 180
    - parameter 171
    - principles of 168–170
    - regulatory assessment and guidelines 180–181
    - risk analysis 179–180
    - settings 177, 179–180
    - terminology 174
  - triangle of project management 18
  - triclinic metazachlor 443–444
  - true molecular solution 332
  - triglyceride oil 342
  - type I lipid-based drug delivery systems 342
  - type IV LBDDS 342
- U**
- ultra-fast heating rates 139–141
  - umbrella effect 116, 118
  - Unitary Patent 431, 433
  - United States patent law
    - amlodipine besylate 428–429
    - cefdinir 427
    - paroxetine hydrochloride (PHC) 424–426
    - ranitidine hydrochloride (RHCl) 426–427
    - tapentadol hydrochloride 423–424
  - United States Pharmacopoeia (USP) 145, 180, 186, 195, 205, 337, 450, 459, 468–469, 471, 514
  - univariate calibration approach 250
  - Universal Series Bus (USB) 407
  - US Food and Drug Agency (FDA) 449, 489, 491
  - U.S. Patent and Trademark Office (USPTO) 54
  - UV-Vis spectroscopy 218–219, 237, 240, 242, 251
- V**
- validation 155–156, 173–174, 180, 181, 196–197
  - Vardenafil hydrochloride 442–443
  - vector network analyzer (VNA) 276
  - very rapidly dissolving 459–460
  - vessels 304
    - choice 230
    - size and MoC 304
- W**
- water insoluble surfactants 342
  - water soluble surfactants 342
  - water-soluble methylcellulose derivatives 70
  - wet dispersion 192–194
  - wet granulation 206, 252–253, 255, 336–340, 348, 351, 475, 498, 517
    - and drying 338–339, 346–347
  - wet-milling 223–224, 302, 306
  - workflow 2, 15, 17, 19, 302, 317, 398, 402, 406, 414
  - workflow management
    - analytic database system 373–375
    - analytic transfer tool 375–376
    - CMC project management 367–368

- workflow management (*contd.*)
    - communication with CROs 381–382
    - crystallization processes 387–388
    - dependencies 370–371
    - designations and code assignment 371–373
    - documentation 378–379
    - ELN documents 379–380
    - fundamental lab processes 382
    - goal 365
    - material flow 371
    - micro-project management 369–370
    - physical sample transfer 375
    - pre-CMC data 369
    - solid-state lab 382–387
    - stability storage process 377–378
    - stakeholders 366–367
    - substance requirement plan 368
    - support processes 388–392
    - timely measurement 376–377
  - World Intellectual Property Organization (WIPO) 54, 56–57, 59–60, 490
  - Wurster process 346
- X**
- X-ray diffraction (XRD) 107
    - advanced phase analysis 124
    - crystal structure 108
    - databases 118
    - detector 115
    - diffraction patterns 116–118
    - diffraction peak 109–110
    - diffractometer geometries 113
      - benchtop diffractometers 115
      - reflection geometry 113–114
  - intrinsic solid properties
    - Debye–Scherrer rings 228, 229
    - ex situ and in situ analysis 231
    - in situ and real time analysis 231, 232
    - sampling restrictions 230, 231
    - structural analysis 228
    - vessel choice 230
    - X-ray sources 230
  - measurement
    - instrument calibration 118–119
    - sample preparation 119
  - peak asymmetry 115–116
  - principle 107, 108
  - qualitative phase analysis 119–120
    - amorphous content 121–122
    - phase identification 120–121
  - quantification 122–123
    - calibration curve 123
    - internal standard addition 123
    - Rietveld refinement 123–124
  - space group symmetry 108–109
  - structure determination 111–112
  - X-ray sources 112–113
- X-ray powder diffraction (XRPD) 1, 16, 19, 22, 28, 70–74, 77, 82–86, 107–124, 137–138, 153–154, 156, 162, 297, 300, 369, 373–375, 377, 379, 383–387, 389, 427, 435, 441, 445, 471, 507, 509, 512
- X-ray powder diffractogram (XRPD) 22, 435, 515
- X-ray scattering technics 110
- Z**
- ZetaSizer™ 222







